



cbIC aps
Associazione Italiana
Acidemia Metilmalonica con Omocistinuria



FALL SEED GRANT 2026

Methylmalonic acidemia with homocystinuria, type cbIC

CALL FOR APPLICATIONS

Introduction

Associazione **cbIC aps – Associazione Italiana Acidemia Metilmalonica con Omocistinuria** (Associazione) and Fondazione Telethon ETS (FT; www.fondazionetelethon.it) have agreed to collaborate to support **18-months** seed research projects focused on **Methylmalonic acidemia with homocystinuria type cbIC**, with a **maximum budget of €75,000**.

The Seed Grant Call is based on the following premises:

- a. Associazione is a non-profit organization dedicated to promoting, disseminating and supporting scientific research on Methylmalonic acidemia with homocystinuria, type cbIC;
- b. FT is a non-profit organization recognized by the Italian Ministry of University and Research, whose mission is to advance biomedical research toward cures for rare genetic diseases by funding research projects through a peer-review process compliant with the UNI EN ISO 9001:2015 standards;
- c. Associazione recognizes FT's peer-review process as a valid method for evaluating and identifying research projects deserving of funding, thereby ensuring a more effective use of financial resources within the research portfolio;
- d. Associazione has expressed its interest in establishing a collaboration with FT, under which: (i) FT will be responsible for preparing the Call, managing the evaluation process for submitted projects, carrying out the post-award administrative procedures, disbursing funds and monitoring scientific outcomes; and (ii) Associazione will be responsible for disseminating the scientific results generated through the funded projects;
- e. Accordingly, Associazione and FT have agreed to collaborate and combine their respective resources to select and manage research projects aimed at advancing scientific progress in Methylmalonic acidemia with homocystinuria, type cbIC.

- f. Associazione hereby irrevocably appoints FT to act on its behalf and authorizes FT to activate project funding in Associazione's sole interest and at Associazione's expense.

Aim of the Call

This Call is in support of research seed projects focusing only and exclusively on **Methylmalonic acidemia with homocystinuria, type cbLC (ORPHA:79282)** to investigate new hypotheses and understand the molecular and pathophysiological mechanisms underlying Methylmalonic acidemia with homocystinuria, type cbLC, and pave the way toward the development of new therapeutic strategies.

Projects aimed at elucidating the pathogenic mechanisms underlying ocular manifestations in early-onset cbLC deficiency, particularly those involving the generation of retinal monolayers and/or ocular organoids as disease models to investigate visual deterioration, are highly encouraged.

Applicants may **submit only one proposal** under the **Fall Seed Grant 2026 Call** and only **single-centre proposals** are admitted.

Applications must be prepared in accordance with the specific guidelines provided. The guidelines and a sample application form are available on the website and platform.

Key Dates

CALL OPENING: **October 14th, 2026**, at this [link](#)

SUBMISSION DEADLINE: **November 16th, 2026, at 1:00 PM (CEST)**

The Study Section will take place **by the end of January 2027**

Notification to applicants of the outcome: **by the end of February 2027**

Although not mandatory, **Applicants are kindly asked to register on the platform and insert *the title, research type, research step, disease name, and ORPHA code* of the proposed project by October 30th, 2026.**

Project Duration

The duration of the proposed project is 18 months.

Eligibility Criteria and Evaluation Process

Eligible Projects

- Research projects focused exclusively on Methylmalonic acidemia with homocystinuria, type cbLC (ORPHA:79282) **are eligible**.
- The following types of research projects are **not eligible** under this Call:

- Epidemiological studies
- Registries
- Biobanks
- Metabolomic studies
- Studies focused on understanding the mechanism of already existing pharmacological treatments
- **Preliminary data are not required**, provided that the underlying scientific rationale and objectives are sound, plausible and testable.

Eligible Host Institutions

Only research proposals submitted by applicants working at Italian public or private non-profit research institutions are eligible. To qualify, the institution must be legally prohibited from distributing profits or surpluses (directly or indirectly) and must ensure that its assets are used for non-profit purposes, including in the event of dissolution. For-profit companies (such as joint-stock or limited liability companies) are not eligible, even if they apply partial or activity-specific restrictions on profit distribution related to research activities.

Applicants affiliated with FT Research Institutes (SR-TIGET and TIGEM) are eligible.

Eligible Applicants

Applicants who currently hold an active grant under another FT funding initiative are eligible to submit a proposal.

Prior experience in the field of Methylmalonic acidemia with homocystinuria type cbLC is not required.

Applicants can **submit only one project** within the round Fall Seed Grant 2026 Call. Please note that Applicants holding an active grant from a different Fondazione Telethon funding initiative are eligible to submit a proposal.

Please note that **Applicants previously funded** through the “**Fall Seed Grant 2024 cbLC Call**” can apply to the present Call with a **new research project**, i.e., substantially different from and not overlapping with the previously awarded grant on Methylmalonic acidemia with homocystinuria type cbLC. Only projects submitted as New Application in the Fall Seed Grant 2024 cbLC Call and **rejected** can be submitted as Revised Applications.

Dual appointments at a foreign institution are permitted, provided that they do not interfere with the proper conduct of the FT-funded research project.

Budget

Applicants may request a maximum budget of €75,000.

For further information on eligible costs, please refer to the *Guidelines for Applicants* and the *Regolamento di Gestione del Finanziamento Seed Grant* for the Fall Seed Grant 2026 CBLC Call, available on the [FT website](#).

A justification must be provided for each budget item. At project closure, an expenses report will be required, and only expenses directly related to the approved project will be approved.

Please note that the Lead Applicant's Host Institution may allocate up to 20% of the total budget to a single collaborator affiliated with a foreign third-party institution, provided that this allocation is indicated clearly in the application. The foreign collaborator's contribution must fall within the scope of the project, evaluated and approved by the reviewers. If approved, the Lead Applicant's Host Institution will be responsible for transferring the funds to the foreign collaborator and for collecting the detailed expenditure documentation to be reported to FT. For more details, please refer to Section III.2 and Section V.4 of the *Regolamento di Gestione del Finanziamento Seed Grant* and the *Guidelines for Applicants* for the Fall Seed Grant 2026 CBLC Call, available on the FT website.

Evaluation Process

Applications that are incomplete and/or do not comply with the requirements set out in this Call and the relevant Guidelines will not be considered for evaluation.

All FT staff and reviewers comply with confidentiality and conflict of interest policies.

FT will first screen all submitted applications to verify their eligibility based on administrative requirements of the Call and their alignment with its scientific scope. Applications that do not meet these criteria will be rejected at this stage.

FT will then appoint an *ad hoc* panel of expert reviewers to evaluate the scientific merit of all eligible Applications.

For clinical trial proposals, FT may also consult experts in clinical trial design and regulatory affairs to further assess the robustness and the feasibility of the proposed study.

All Reviewers involved in the evaluation process will be bound by strict confidentiality and conflict of interest rules defined by FT.

Remote Evaluation

Reviewers will evaluate and score each proposal according to the following criteria:

A) Scientific merit:

- Significance
- Scientific originality
- Appropriateness of design and methods
- Feasibility and safety
- PI and research team competence
- Budget

B) Potential impact:

- Added value: If successful, how will the project advance current scientific knowledge in the field?
- Unmet need: How will the project address the unmet need/s of patients affected by the rare genetic disease?

Reviewers' evaluation guidelines are available on the FT website.

Study Section

Top-scoring proposals will be discussed by an *ad hoc* panel of expert reviewers during a study section, scheduled to take place **by the end of January 2027**. Following the discussion, all Reviewers will assign a final score to each proposal.

Outcome of the Evaluation Process

Applicants will be notified of the outcome by email **by the end of February 2027** and will receive instructions on how and when to access the FT Review Report on the *FT Grant Management* system.

Awardees will receive separate administrative instructions via email to initiate the grant activation process.

FT Policies and Rules

FT, as a member of the International Research Disease Consortium ([IRDiRC](#)), endorses and applies the IRDiRC Policies and Guidelines, which “emphasize collaboration in rare diseases research, the involvement of patients and their representatives in all relevant aspects of research, and the sharing of data and resources.”

In addition, all FT Applicants and Grantees are bound to comply with the policies reported below.

Safeguarding Research Integrity

Research Integrity (RI) is the basis of responsible conduct of research (RCR); the core principles of RI – *reliability, honesty, respect, accountability* - are widely recognized across the international scientific community, as laid out by [the European Code of Conduct for Research Integrity](#).

FT is fully committed to preserving and promoting the RCR within the FT-funded research community, to ensure and strengthen high-quality research and to maintain public trust in its research enterprise.

Applicants, Grantees and all research personnel (investigators, trainees, administrators and staff) related to any FT Application or FT project must strictly adhere to the highest standards of good research practices, which embrace the following contexts: research environment, training, supervision and mentoring, research procedures, safeguards, data practices and management, collaborative working, publication and dissemination, reviewing, evaluating and editing.

Potential research misconduct will result in FT issuing a formal notification to the Applicants' Host Institution, which should then respond according to its policy for handling allegations of research misconduct.

In particular, FT expects that organizations where the FT-funded scientists work:

- have policies, structures and training in place that enable students and researchers to understand and adopt good research practices.
- have formal, written policies for preventing and dealing with scientific misconduct, conventionally defined as fabrication, falsification, or plagiarism but including other unacceptable practices, including, but not limited to, manipulating authorship, 'self-plagiarism', withholding research results, misrepresenting research achievements, and misusing seniority to encourage violations of research integrity.

Please see the FT guidelines on Research Integrity at the following [link](#).

Awarding of Research Funds

Awarded funds must be used exclusively for the implementation of the approved research project. FT requires all funds to be managed efficiently and cost-effectively, and all expenditures to be necessary and directly related to the approved project activities.

No funds will be disbursed by FT to any Host Institution until a specific agreement has been duly executed by both parties according to art. 3 of the D.P.R. 20th March 2003, n. 135.

FT reserves the right to ask for a copy of the statute of the Host Institution and of the latest available balance sheet as well as the acknowledgment of the legal status for all the Applicants working for non-profit private organizations; equally, FT can request updates of the statute and of the balance sheet in the case of Applicants working for non-profit organizations that have already benefited from FT funds in the past. FT reserves the right to evaluate the compatibility of the statutory guidelines of the private institutions on a case-by-case basis, to ensure social benefit and financial reliability in order, if necessary, to dictate the conditions for the assignment/payment of the contribution.

FT reserves the right to visit the Host Institution before releasing any funds and at any time during the grant period.

The funds will be disbursed in two tranches:

- Fifty percent will be disbursed after the submission of all required documentation, as specified in the present Call for Applications and in the *Regolamento di Gestione del Finanziamento Seed Grant* document for the Fall Seed Grant 2026 CBLC Call.
- The remaining fifty percent will be reimbursed upon completion of the project, submission of the final scientific report and approval of the administrative report demonstrating that all granted funds have been spent. Should there be any unspent residue, only the amount that has been spent will be reimbursed.

FT reserves the right to cancel payments whenever a conflict arises regarding the stipulations contained in this Call for Applications, or stipulations specifically made by FT to the Host Institution and/or Applicant.

Publications, Data Sharing and Final Scientific Reports

The Grantee is required to:

1. Acknowledge **cbIC aps – Associazione Italiana Acidemia Metilmalonica con Omocistinuria** and FT in all publications arising from the project (also by specifying the **project number** in the Acknowledgements/Funder section) and send the PDF file to papers@fondazionetelethon.it;
2. Comply with the FT **Open Access Policy** (<https://www.fondazionetelethon.it/en/what-we-do/support-of-research-and-patients/support-to-research/open-access/>);
3. Deposit data generated from the research project, including source data, on appropriate open or controlled access public databases;
4. Comply with the European General Data Protection Regulation no. 679/2016 as well as with any other applicable local law;
5. Submit the Final Scientific Report at the end of the project;
6. Support **cbIC aps – Associazione Italiana Acidemia Metilmalonica con Omocistinuria** to disseminate data generated from the research project.

Development of FT Funded Research Results

1. FT acknowledges that full ownership of all intellectual property (IP) rights arising from funded research belongs to the Host Institution/Grantee, according to IP regulations and without prejudice to the rights of potential third-party collaborators.

2. FT acknowledges the need to translate research results into therapies and to make them available to patients and recognizes that this can be achieved through the activation of industrial collaborations and partnerships that may accomplish the development, manufacturing and distribution of therapies, drugs, diagnostics and devices. FT requests that the Grantee and the Host Institution undertake all the steps required to ensure adequate protection and seek opportunities for the development of such research results.
3. Accordingly, the Grantee is required to ensure that any potential therapeutic/diagnostic approach arising from the funded research project is duly protected by a patent application through the interaction and cooperation with the Host Institution's Technology Transfer Office (or other relevant office) before its disclosure (i.e., abstracts, posters, oral presentations, papers). To this aim, the Grantee must share all disclosures with the Host Institution's Technology Transfer Office in due time for the necessary assessments of patentability and patent filing procedures.
4. To allow FT to monitor the outcomes of the research funded, the Host Institution must inform FT (tto@fondazionelethon.it) via written communication of any new patent filings related to the project.
5. In addition, the Host Institution shall promptly inform FT in writing if it decides not to proceed with the protection of a patentable result or with the exploitation or prosecution of a filed patent. In such cases, FT will evaluate, together with Associazione, the type of activity to be undertaken, and the need to formalize a specific mandate to conduct such activities.

Privacy of Personal Data

FT and the Host Institution shall act as independent data controllers with respect to the personal data processed in connection with the application.

The Host Institution is allowed to indicate the personal data of the Applicant as well as of any other researcher involved in the application, on the condition that the Host Institution: (i) has provided the involved researchers with the information about privacy policy reported on the grant tracker platform and available to download on the website; (ii) has thereby gathered the relevant consents; and (iii) will approve the application ensuring that the above conditions have been respected.

FT shall, at any time, have the right to examine such documents (information to data subjects and declaration of consent) at the Host Institution location. The Host Institution shall deliver any document, according to the FT request.

In the partnership between Associazione and FT, FT is entrusted with managing the evaluation process of the research projects, the post-award administrative procedures and the scientific monitoring that are carried out through its own tools and means. Therefore, only FT is allowed to know the personal data deriving from

the evaluation process and from the administrative procedures that follow the fund allocation. No personal data will be transmitted by FT to Associazione except for specific and justified reasons in which FT may communicate to Associazione the personal data acquired only after having transmitted to the interested party the information pursuant to art. 13 of the REG.EU n. 679/2016 of Associazione and obtained the relevant consent for the processing of personal data.

Therefore, for privacy purposes, FT is the data controller, while Associazione has no role (given that Associazione does not know the personal data).

Milan - October 14th, 2026

FONDAZIONE TELETHON ETS